A Phase I/II Study of Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC).
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 29 Apr 2017
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Temsirolimus (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Apr 2017 Planned End Date changed from 1 Nov 2017 to 1 Nov 2018.
- 25 Apr 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.
- 25 Apr 2016 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017.